|
ZA201103984B
|
|
Toll-like receptor 3 antagonists
|
|
CA2800744A1
|
|
Insulin-like growth factor 1 receptor binding peptides
|
|
WO2011115884A1
|
|
Diagnostic for lung cancer using mirna
|
|
CN103096934A
|
|
Non-aqueous high concentration reduced viscosity suspension formulations
|
|
WO2011112511A1
|
|
Methods and algorithms for selecting polynucleotides for synthetic assembly
|
|
WO2011059660A2
|
|
Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
|
|
CN102665805A
|
|
Palm activated drug delivery device
|
|
WO2011031757A1
|
|
Serum markers for identification of cutaneous systemic sclerosis subjects
|
|
CN102482643A
|
|
Differentiation Of Human Embryonic Stem Cells
|
|
CN102576015A
|
|
Serum markers predicting clinical response to anti-TNF[alpha] antibodies in patients with psoriatic arthritis
|
|
WO2010093627A2
|
|
Fibronectin type iii domain based scaffold compositions, methods and uses
|
|
BRPI0923806A2
|
|
Serum markers for predicting clinical response to anti-tnfa antibodies in patients with ankylosing spondylitis.
|
|
CN102257132A
|
|
Methods and compositions for cell attachment and cultivation on planar substrates
|
|
EP2352998A2
|
|
Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
|
|
WO2010045340A1
|
|
Methods of humanizing and affinity-maturing antibodies
|
|
CA2739083A1
|
|
Translocation interfering toll-like receptor 3(tlr3) variants for suppressing toll-like receptor activity and uses thereof
|
|
WO2010039615A2
|
|
Papio cynocephalus toll-like receptor 3
|
|
CN102165315A
|
|
Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel
|
|
CN102159281A
|
|
Stimulation of satiety hormone release
|
|
AU2009303821A1
|
|
Biomarkers for anti-TNF treatment in ulcerative colitis and related disorders
|
